My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

181.71 +0.96 (+0.53%)

Streaming Delayed Price Updated: 1:53 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

56 57 Next >

If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗

August 14, 2023

Via Benzinga

Why Shares of Sage Therapeutics Slumped This Week ↗

August 11, 2023

The company got bad news from the FDA and saw increased losses.

Via The Motley Fool

Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? ↗

August 10, 2023

The company's rare disease portfolio may soon get an upgrade.

Via The Motley Fool

With an Acquisition on the Way, Is Biogen Stock a Buy? ↗

August 09, 2023

Can the biotech finally get back in the good graces of investors?

Via The Motley Fool

Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? ↗

August 09, 2023

Lilly shares surged 15% in one day to a record high. Here's what you should know.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)

August 08, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Looking Into Biogen's Recent Short Interest ↗

August 08, 2023

Via Benzinga

Is Sage Therapeutics a Contrarian Buy? ↗

August 08, 2023

A regulatory setback weighed heavily on the drugmaker's shares Monday.

Via The Motley Fool

DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

August 08, 2023

Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...

Via Benzinga

What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter

Via Benzinga

Dow Rises Over 300 Points To Start The Week ↗

August 07, 2023

The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.

Via Talk Markets

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

Biogen Unusual Options Activity For August 02 ↗

August 02, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗

July 31, 2023

Via Benzinga

PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗

August 07, 2023

Benzinga

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 07, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗

August 07, 2023

The company gained approval for the first oral treatment for postpartum depression.

Via Investor's Business Daily

FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with

Via Benzinga

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Sage Therapeutics, Inc.

Via Business Wire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Biogen Inc.

Via GlobeNewswire

3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now ↗

August 02, 2023

Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites.

Via InvestorPlace

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗

August 01, 2023

Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)

August 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. ↗

August 01, 2023

Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.

Via The Motley Fool

Rising Stars, Falling Trends: July's Industry ETF Winners And Losers ↗

July 31, 2023

Via Benzinga

Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen ↗

July 31, 2023

By 2024, their medicines will likely be competing on the market, and one might win.

Via The Motley Fool

Could This Stock Be the Next Biotech Buyout? ↗

July 31, 2023

A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.

Via The Motley Fool

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes ↗

July 30, 2023

Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.

Via InvestorPlace

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗

July 29, 2023

There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)

July 28, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.